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Introduction: The purpose of this study was to evaluate the presence and levels of interferon-gamma inducible
protein-10 (IP-10) in the plasma and skin of pediatric localized scleroderma (LS) patients compared to those of
healthy pediatric controls and to determine if IP-10 levels correlate to clinical disease activity measures.
Methods: The presence of IP-10 in the plasma was analyzed using a Luminex panel in 69 pediatric patients with
LS and compared to 71 healthy pediatric controls. Of these patients, five had available skin biopsy specimens with
concurrent clinical and serological data during the active disease phase, which were used to analyze the presence
and location of IP-10 in the skin by immunohistochemistry (IHC).
Results: IP-10 levels were significantly elevated in the plasma of LS patients compared to that of healthy controls
and correlated to clinical disease activity measures in LS. Immunohistochemistry staining of IP-10 was present in the
dermal infiltrate of LS patients and was similar to that found in psoriasis skin specimens, the positive disease
control.
Conclusions: Elevation of IP-10 levels in the plasma compared to those of healthy controls and the presence of
IP-10 staining in the affected skin of LS patients indicates that IP-10 is a potential biomarker in LS. Furthermore,
significant elevation of IP-10 in LS patients with active versus inactive disease and correlations between IP-10 levels
and standardized disease outcome measures of activity in LS strongly suggest that IP-10 may be a biomarker for
disease activity in LS.Introduction
Scleroderma, a connective tissue disease characterized
by cutaneous sclerosis, is a broad term that encompasses
both forms of the disease: systemic sclerosis (SSc) and
localized scleroderma (LS), also known as morphea. SSc
is a systemic disorder characterized by skin, vascular and
visceral organ sclerosis, which more commonly affects
adults. LS, which is more prevalent in children, is cha-
racterized by sclerosis that is typically limited to the
skin, subcutis, and underlying bone and tissue without
vascular or internal organ involvement. Although both
SSc and LS share a common underlying pathophysiology
of excessive production and deposition of collagen and
sclerosis in an autoimmune setting, they are clinically
different with unique morbidities and prognoses. LS has* Correspondence: kathryn.torok@chp.edu
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stated.a different pattern of morphology and skin lesion distribu-
tion than SSc; it encompasses several subtypes including
plaque morphea (circumscribed superficial), generalized
morphea, linear scleroderma of the trunk/extremities or
head, deep morphea (circumscribed deep), pansclerotic
morphea and mixed morphea [1].
Though the dermatopathology of these entities is similar
and sometimes difficult to differentiate, there are a few
characteristics which dermatopathologists document as
occurring more frequently in LS compared to SSc, such as
more overlying epidermal atrophy, more intense inflam-
mation and more diffuse dermal sclerosis [2]. Both LS and
SSc share findings of an earlier active disease phase with
newer lesions demonstrating a lymphocytic infiltrate with
a variable number of plasma cells and eosinophils [2]. As
lesions evolve, inflammation density decreases as collagen
bundles thicken and skin sclerosis increases in the later
fibrotic phase of the disease [2].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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associated with several cytokines and chemokines. In
addition to playing a role in the physiological process of
immune cell maturation and trafficking, chemokines
induce, maintain and amplify inflammatory and immune
reactions [3]. Previous reports suggest that cytokines of
various T-helper cell lineages contribute to both forms of
scleroderma, LS and SSc [4,5]. An inflammatory chemo-
kine of interest in this study, interferon-gamma inducible
protein-10 (IP-10, CXCL10), belongs to the CXC chemo-
kine subfamily and is known to play a role in inflamma-
tory responses in several autoimmune diseases, including
systemic lupus erythematosus [6], juvenile dermatomyo-
sitis [7] and SSc [5,8]. IP-10 acts through CXCR3 recep-
tors that attract Th-1-type lymphocytes to inflammatory
sites in the skin and contributes to several skin diseases,
including psoriasis [9]. Interferon-gamma (IFN-γ) stimu-
lates the secretion of IP-10 from keratinocytes and other
immune cells, including leukocytes, neutrophils, eosino-
phils, macrophages and monocytes, which induces an
inflammatory response [3]. Activated Th cells, B cells,
macrophages and NK cells express CXCR3 and are then
attracted to the inflamed tissue areas by IP-10 [3], which
may account for the inflammatory infiltrate present in the
skin of scleroderma patients.
In regards to scleroderma, most studies to date have
focused on IP-10 expression in SSc. IP-10 expression is
elevated in the serum [5], plasma [8] and skin [10] of
SSc patients compared to that of healthy controls, and
levels reflect active disease [5,8]. Furthermore, recent
studies in SSc have shown that elevated plasma IP-10
levels correlate significantly with the Medsger Severity
Index for muscle, skin and lung involvement and thus
act as a serological marker of disease severity [8]. How-
ever, the expression of IP-10 in the peripheral circulation
and skin of LS patients has not been studied. Thus, this
study was designed to evaluate IP-10 in the circulation
and local tissue in LS patients, with the additional goal




The University of Pittsburgh Institutional Review Board
(IRB) approved four separate protocols for (1) blood sam-
ple and clinical data collection of LS patients, (2) blood
sample collection from de-identified healthy controls, (3)
skin sample analysis of LS patients and (4) skin sample
analysis of de-identified controls. Blood sample and cli-
nical data collection of LS patients was performed through
the National Registry of Childhood Onset Scleroderma
(NRCOS) which has been approved by the University of
Pittsburgh IRB since 2003. Consent was obtained from
parents for their children’s participation in the NRCOSstudy and assent was obtained when appropriate. Healthy
plasma control samples were obtained through an IRB
approved protocol to collect and store discarded ‘waste’
samples resulting from well child visits at the University
of Pittsburgh. The study team was not involved in this
sample collection. After making a request to this protocol,
an honest broker provided the study team with de-
identified samples. Only basic demographic information
associated with the healthy plasma was given to the study
team, including age and sex.
For skin sample analysis, waivers of informed consent
were granted by the IRB for two separate protocols; one
to access retrospective LS patient skin specimens and
one to access healthy and disease control samples. The
IRB approved the waivers of informed consent after
determining the protocols were minimal risk and the
waivers did not adversely affect the rights and welfare of
the subjects. Samples from LS patients were collected as
part of clinical care, stored in the dermatopathology
laboratory and accessed retrospectively by the study
team. An honest broker was used to procure the control
skin samples from the dermatopathology laboratory,
which were given to the study team in a de-identified
manner.
The study of IP-10 in the plasma of LS subjects was
performed first and included subjects with both active
and inactive disease states. Subjects from this study who
had available skin biopsy specimens with concurrent
clinical and serological assessment during the active
phase of disease were included in the immunohisto-
chemisty IP-10 staining study.
Blood specimen collection and clinical data
All LS patients had clinic visits from 2003 to 2012, during
which standardized demographic, clinical and laboratory
data were collected. Research blood samples were ob-
tained from subjects by venipuncture at routine clinical
visits as part of their participation in the pediatric sclero-
derma registry at the Children’s Hospital of Pittsburgh.
Plasma was separated from whole blood via density-
gradient centrifugation at 4°C within four hours of blood
collection and promptly stored in 200 μL aliquots at −80°C
until experimentation.
At the concurrent visit in which plasma was obtained,
standardized clinical LS outcome measures were col-
lected, including two disease activity measures: physician
global assessment of activity (PGA-A) and the modified
Localized Scleroderma Skin Score (mLoSSI) [11]. The
PGA-A is usually completed in conjunction with the
mLoSSI, and both outcome measures were used to
determine if the patient’s disease status at the time of
sample collection was ‘active’ or ‘inactive’. The PGA-A is
graded on a 100-mm analog scale and includes the fol-
lowing cutaneous variables: new lesions within the
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previous month, erythema/violaceous color at the border
of lesion and skin thickening/induration at the border of
lesion [11]. The mLoSSI includes the sum of three sepa-
rate scores from the following domains: erythema (none,
mild, moderate, severe), skin thickness (none, mild, mo-
derate, severe) and new lesion/lesion extension (present,
not present) [11]. A patient was classified as having active
disease if they had a PGA-A greater than zero and a
mLoSSI greater than zero. The only available demographic
information obtained for the de-identified healthy plasma
controls was their age and gender. These samples were
obtained at well child evaluations at the University of
Pittsburgh, and, therefore, should represent a similar
population.
Cytokine measurement
Plasma IP-10 levels (detection limit: 7.5 pg/ml to
10,000 pg/ml) were measured using the Luminex bead
immunoassay system (BioRad, Hercules, CA, USA),
according to the manufacturer’s instructions at the
University of Pittsburgh Cancer Institute (UPCI) Lumi-
nex Core Facility. The plasma samples were undiluted
and compared to a High PMT-Standard Dilution Series
(BioRad, Hercules, CA, USA). To investigate the reliability
of the samples included in the Luminex analysis, levels of
IP-10 in the plasma of subjects (LS and healthy) were
measured in duplicate. Inter-panel and intra-assay control
plasma samples were included to ensure consistency
across panels.
Tissue specimen collection
All skin specimens were accessed retrospectively by the
study team per approved IRB protocols. The LS subjects’
skin specimens of interest included those with plasma
IP-10 analysis during the active state of disease (typically
their first clinical visit to the scleroderma center) with
concurrent clinical assessment performed within a few
months of the biopsy. Both the biopsy and plasma speci-
mens of these subjects (n = 5) were obtained before any
systemic therapy was initiated. At our center, typically
the dermatologists will obtain a skin biopsy to confirm
the diagnosis and then quickly refer to the pediatric
rheumatology service in Pittsburgh for further manage-
ment. The skin specimens from pediatric LS, psoriasis
and healthy subjects consisted of residual tissues from
4 mm punch biopsies obtained for clinical purposes. All
of the skin biopsies were performed by dermatologists at
the University of Pittsburgh Medical Center, not by the
patient’s treating rheumatologist or member of the study
team. Samples were processed and stored according to a
standard clinical protocol with immediate immersion in
formalin for 24 to 48 hours, followed by fixation in par-
affin for long term storage. Once requested by the studyteam, the paraffin blocks were made accessible for im-
munohistochemistry (IHC) analysis.
Immunohistochemistry
Immediately prior to experimentation, the paraffinized
block specimens were sectioned into 6 μm sections and
fixed onto glass microscopy slides. IHC was performed on
serial skin biopsy sections. Tissue was de-paraffinized in
xylene and rehydrated sequentially in ethanol. Antigen re-
trieval was carried out using a steamer and endogenous
peroxidases were quenched to reduce non-specific back-
ground staining. The tissue was blocked using 5% goat
serum 4% BSA blocking buffer according to standard
protocol. The tissue was then analyzed for the presence
and location of IP-10 staining. To decrease variability, du-
ring the analysis of each individual LS patient, a psoriasis
disease control and healthy control specimen were studied
in tandem. Psoriasis was chosen as a positive disease con-
trol because IP-10 staining has been demonstrated in the
dermis, as has been shown by Giustizieri et al. [9].
For each subject, a section of tissue was incubated over-
night in the primary antibody, polyclonal IP-10 (1:250;
Amgen Inc., Thousand Oaks, CA, USA) and the second
section of the corresponding tissue was incubated over-
night in the rabbit immunoglobulin G (IgG) isotype con-
trol (1:1000; Vector Laboratories, Inc., Burlingame, CA,
USA) to serve as an antibody control. Following the pri-
mary antibody incubation, all tissue sections were washed
in PBS and incubated with secondary antibody, biotinyl-
ated anti-rabbit IgG (1:200; Vector), for 30 minutes. The
tissue was washed in PBS and incubated in Avidin Biotin
Complex (ABC) (Vector) and aminoethylcarbazole solu-
tion (AEC) (Life Technologies Corporation, Carlsbad, CA,
USA) for detection purposes. Images were acquired using
an Olympus Provis microscope (Olympus America Inc.,
Center Valley, PA, USA).
Hematoxylin and eosin staining
To assess the presence and degree of cellular infiltration
in the skin sections, hematoxylin and eosin (H & E)
staining was carried out according to standard protocol
in skin sections adjacent to those used for IHC.
Data analysis
Luminex assay
All analyses were performed using SPSS v. 20 (SPSS,
Chicago, IL. USA). Mean or median was used to de-
scribe data where appropriate. To determine if variability
was present in the Luminex results between duplicate
samples, intra-class correlation coefficients (ICC) were
calculated. ICC values were interpreted according to the
following ranges: excellent reproducibility: 0.6 to 1.0,
moderate reproducibility: 0.4 to 0.59, and poor reprodu-
cibility: <0.4 [12].
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ferences in IP-10 plasma levels between subject groups
using Wilcoxon rank sum analyses (α level of 0.05). IP-10
plasma levels were compared between LS and healthy
controls, as well as within LS between active and inactive
disease (activity classification based on clinical para-
meters). The relationship of cytokines to clinical measures
of disease activity (PGA-A and mLoSSI) were also exam-
ined using Spearman’s rho (nonparametric correlation).
Correlations of 0.16 to 0.29 were considered weak to low,
0.3 to 0.59 moderate to low, 0.5 to 0.69 moderate, 0.7 to
0.89 strong, and 0.9 to 1 very strong. Finally, IP-10 levelsTable 1 Demographic and baseline characteristics of 69
localized scleroderma (LS) subjects and 71 healthy
control subjects who were included in the plasma
analysis
Characteristics LS patients Healthy controls
(number = 69) (number = 71)
number (%) number (%)
Female 46 (66.7) 38 (54)
Caucasian 63 (91) unknown
Median (IQR) Median (IQR)
Age at plasma sample
in years
12.5 (10.0 to 16.0) 3 (2.0 to 9.0)
Age at disease onset
in years

































PGA-A 41.0 (29.0 to 62.0) —
mLoSSI 6.0 (3.0 to 13.0) —
IQR, interquartile range; mLoSSI, modified Localized Scleroderma Skin Score;
PGA-A, physician global assessment of activity.within classification subgroups of LS were compared to
determine any differences. Subgroup classification was
based on the Padua criteria [1].
Tissue analysis
The tissue was analyzed for the presence and location of
IP-10 staining. To evaluate the general degree of in-
flammatory infiltrate in the tissue sectioned, a dermato-
pathologist (JH) also evaluated the H & E slides which
corresponded to the IP-10 stained tissue per subject. He
described the cellular infiltrate present and scored the
degree of cellular infiltrate in three random high power
fields (HPF) per LS tissue section to determine the ave-
rage amount of inflammation per specimen (mild, mode-
rate, severe). The degree of infiltration in each HPF was
quantified according to the following scale: mild: 1 to 50
cells, moderate: 51 to 150 cells, severe: >150 cells.
Results
Plasma analysis of IP-10
Plasma analysis included 69 patients with LS and 71
healthy children. Demographic and clinical data were
obtained and are summarized in Table 1. This sample of
LS subjects is representative of other large cohorts of
pediatric LS patients [13]. The ICC between duplicate
Luminex samples was very high (ICC = 0.996) indicating
excellent reproducibility of IP-10 levels and, thus, the







Healthy      LS (overall)      Active LS     Inactive LS
n =        71 69 30 39
Median = 445.8 1140.3 2087.3 880.5
IQR = (246.0 –833.5)  (497.9 –2495.7)    (956.6 –3099.0)  (447.8 –1289.8)
Figure 1 IP-10 levels are increased in patients with localized
scleroderma. Plasma IP-10 levels in pediatric localized scleroderma
(LS) patients, as a whole group, and then divided into active and
inactive disease, compared to that of healthy controls. IP-10 levels in the
plasma were significantly higher in pediatric LS patients in comparison
to healthy controls, and those LS subjects with active disease had
significantly higher levels than those with inactive localized scleroderma.
IP-10, interferon-gamma inducible protein-10.
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IQR = 497.9 to 2,495.7) were significantly elevated com-
pared to those of healthy controls (median = 445.8 pg/ml,
IQR = 246.0 to 833.5, P <0.001) (Figure 1). When disease
activity status in LS patients was classified based on the
above mentioned clinical parameters (mLoSSI and PGA-A
greater than 0), 30 patients (43%) were considered to have
active disease and 39 patients (57%) were considered to
have inactive disease at the time of sample collection.
Forty-two patients (61%) were on systemic therapy at the
time of blood draw, with the majority being on metho-
trexate (36/42), either alone or in combination with pred-
nisone. Three were on prednisone alone and there was
one on each following: imuran, doxycycline and inflixi-
mab. The average duration of therapy for this group was
27.5 months. The remaining 39% (27/69) were not on
systemic therapy at the time of blood draw; most of these
patients (22/27) were in the active disease group (typically
reflecting their first rheumatology visit).
IP-10 levels were significantly higher in active LS pa-
tients (median = 2,087.3 pg/ml, IQR = 956.6 to 3,099.0)
compared to inactive LS patients (median = 880.5 pg/ml,
IQR = 447.8 to 1,289.8, P = 0.001) (Figure 1). IP-10 levelsTable 2 Demographics, clinical activity measures and IP-10 an
(psoriasis and healthy) participating in tissue analysis










Linear (trunk/limb) 3 (60
Plaque (circumscribed superficial) 2 (40
Age Median
Age at onset, years 13 (6 to
Age at biopsy, years 13 (10 to
Tissue analysis Number
IP-10 staining present in cellular infiltrate 5 (100
Degree of cellular infiltratea
Mild (1 to 50) 3 (60
Moderate (51 to 150) 2 (40
Clinical measures and plasma IP-10 of LS patientsb Median
PGA-A 48 (41 to
mLoSSI 7 (7 to
Plasma level of IP-10 (pg/ml)c 2,814 (745 t
aAverage cellular infiltrate in skin: out of three high power fields: 1 to 50 =mild; 51
first pediatric rheumatology visit, which was within 12 weeks of the biopsy date; cd
IQR, interquartile range; mLoSSI, modified Localized Scleroderma Skin Score; PGA-Ain the plasma of LS patients had moderate to low, but
statistically significant, correlations with scores of both
clinical disease activity measures, the PGA-A (rs = 0.45,
P <0.001) and mLoSSI (rs = 0.34, P = 0.004).
Tissue analysis of IP-10
Of the 69 LS patients included in the luminex study, five
had skin biopsies available which were taken within the
12 weeks (median 2 weeks, IQR 2 to 8 weeks) preceding
their first rheumatology clinical visit, where the plasma
and disease activity measures were obtained. These five
subjects were determined as active based on their mLoSSI
and PGA-A scores as well as being naive to systemic
medication and were included in the IHC analysis of
IP-10. The site of the biopsy for all patients was performed
at the leading edge of a lesion (considered the most active
site) and the lesion itself was considered active by both
the dermatologist and rheumatologist. Clinical activity
scores at the time of first rheumatology visit/blood draw
were relatively high with a median PGA-A of 48 and a
median mLoSSI of 7 (see Table 2 for clinical features).
Plasma IP-10 levels of these five subjects reflected the
active subgroup of LS subjects (described above) with aalysis of localized scleroderma (LS) patients and controls
ects Healthy controls Psoriasis controls
= 5) (number = 2) (number = 2)
(%) Number (%) Number (%)
) 1 (50) 2 (100)




(IQR) Ages in years Ages in years
16) — —
16) 17, 18 34, 47
(%) Number (%) Number (%)
) 0 (0) 2 (100)
) 2 (100) 0 (0)




o 3,081) — —
to 150 =moderate; >150 severe; bclinical and plasma measures obtained at
etermined by Luminex assay. IP-10, interferon-gamma inducible protein-10;
, physicians global assessment of activity.
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Skin specimens were also obtained from two healthy
controls, a Caucasian male, age 18, and an African
American female, age 17 (Table 2). Two psoriasis di-
sease control skin samples from a 47- and a 34-year-old
woman were examined (Table 2).
When healthy human skin was stained for the expres-
sion of IP-10 no staining of the dermis was observed. In
LS patients, IP-10 staining was observed in the super-
ficial and deep dermal perivascular lymphoplasmacytic
infiltrate (Figure 2). Examination of the two psoriasis
skin biopsies demonstrated a moderate superficial pe-
rivascular and interstitial inflammatory infiltrate, con-
sisting of lymphocytes and neutrophils, which stained
positively for IP-10 (Table 2). The histological analysis of
the H & E slides of the five LS patients by the derma-
topathologist (JH) identified the presence of a mild-
moderate degree of lymphoplasmacytic inflammation in
all slides (Table 2).
Discussion
This study demonstrated IP-10 to be significantly elevated
in the peripheral circulation of pediatric patients with LS









Figure 2 IP-10 is identified in patients with localized scleroderma skin
of IP-10 was performed on localized scleroderma, psoriasis (as positive control
hematoxylin and eosin (H & E) to visualize cellular infiltrate (A, D, G, J). All spe
absence of IP-10 staining for the control (B, E, H, K). There was an absence of
out of two subjects). The psoriasis disease controls demonstrated moderate st
subjects). Localized scleroderma (LS) patients demonstrated moderate IP-10 st
five subjects). IgG, immunoglobulin G; IP-10, interferon-gamma inducible protefindings in adult SSc studies in both Caucasian [10,14]
and Japanese cohorts [5,15]. In addition, IP-10 was also
present in the local tissue directly affected by LS. Finally,
we found significant positive correlations between vali-
dated and prospectively collected disease activity para-
meters (mLoSSI and PGA-A) and plasma IP-10 levels,
supporting a potential role of IP-10 in the active disease
phase of LS. This is the first time IP-10 levels have been
demonstrated to correspond to disease activity measures
in LS. In adults, SSc studies have also demonstrated IP-10
in the plasma to correlate with disease activity and severity
parameters, including skin thickness [8].
A greater understanding of the origin of IP-10 in skin
sclerosis is required to develop effective therapies for LS.
An increased expression of IFN-inducible chemokines
(IP-10) is most likely a response to the high IFN-γ skin
levels in early stages of disease [14]. IFN gene expression
studies in SSc have shown that SSc patients have higher
serum [14] and plasma IFN-inducible chemokine levels
that correlate with microarray and qPCR IFN gene ex-
pression scores when compared with those of healthy
controls [8].
In many Th-1-dominant autoimmune disorders, it has





specimens, similar to psoriasis. Immunohistochemical (IHC) analysis
) and healthy patient skin specimens. All skin specimens were stained with
cimens were also stained using an IgG control and demonstrated the
IP-10 staining in healthy controls represented by panel C (one illustrated
aining for IP-10, represented by panel F (one illustrated out of two
aining in the dermis, represented by panels I and L (two illustrated out of
in-10.
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flamed tissue and in the process of tissue damage [16].
Both LS and SSc are characterized by a predominant
lymphocytic infiltrate during the active phase of the
disease. The exact lymphocyte cell type has not yet been
identified in LS, but studies in SSc demonstrate a mixture
of CD8+ and CD4+ cells in affected skin [17]. It is possible
that Th-1 cells, a subset of CD4+ T-helper cells, may be
recruited locally to the site of the skin by IP-10. IP-10
belongs to the CXC chemokine family, known lymphocyte
attractants, predominantly in areas of inflamed tissue [3].
In LS, the active phase, which has previously been shown
to be induced by T cell-derived cytokines, is followed by a
damage phase characterized by sclerosis [18]. The result
of sclerosis and atrophy of the skin and underlying tissues
may cause significant deformity and severe functional
impairment [19]. Thus, it is essential to target potential
pathogenic inflammatory proteins, such as IP-10, in the
active inflammatory phase of LS to minimize cumulative,
permanent disease damage.
To our knowledge, this is the first study which pro-
vides evidence of IP-10 as a possible biomarker for LS.
However, this study is limited due to its cross sectional
nature and small sample size, specifically for the results
pertaining to skin samples. Also, the healthy control
plasma samples were as a whole, younger than the LS
patients. It would be interesting to evaluate if these
results were replicable in a group of LS patients with age
matched controls. A longitudinal approach of the peri-
pheral blood IP-10 expression as disease status changes
with systemic therapy is currently being undertaken by
our study team and would assist in further defining
IP-10’s role as a disease activity biomarker or predictor.
Our ultimate goal in the investigation of the biologic
contribution of IP-10 and the IFN pathway to disease
activity will hopefully aid in the development of more
directed and efficacious therapies.Conclusions
Our study indicates IP-10 as a potential clinically action-
able biomarker in localized scleroderma by reflecting
active disease, which may be useful for clinical manage-
ment, such as medication response. Future directions in-
clude longitudinal analysis of peripheral IP-10 levels as the
disease transitions from active to inactive states and later
flares.
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